Canada launches antitrust probe into Cigna's Express Scripts unit

Reuters
04-11
UPDATE 1-Canada launches antitrust probe into Cigna's Express Scripts unit

Adds details and background throughout

April 11 (Reuters) - Canada's Competition Bureau said on Friday it has started an investigation into Cigna's CI.N pharmacy services unit Express Scripts' alleged anti-competitive conduct that could prevent or limit competition in the country's drug retail market.

The agency said it is looking into Express Scripts' alleged "patient steering" to make people use pharmacies owned or associated with its Canada unit, instead of a drugstore of the patient's choice.

The bureau is also looking into practices that are reducing the margins of its retail pharmacies.

Cigna did not immediately respond to a Reuters request for comment.

Express Scripts has the largest pharmacy benefit management operations in Canada, according to the Canadian Pharmacists Association (CPhA).

The association had last year filed a complaint with the antitrust agency alleging "longstanding and exploitative practices" by the company. It was not clear if the probe was due to the CPhA's complaint.

Express Scripts provides prescription drug claim processing and other services for insurance providers and pharmacists and operates four mail-order pharmacies across Canada, except for Quebec, according to the agency.

The agency said an order granted by the federal court requires Express Scripts Canada to produce records and written information, and provide oral testimony, that are relevant to its investigation.

There is no conclusion of wrongdoing at this time, the bureau said.

(Reporting by Sneha S K in Bengaluru; Editing by Leroy Leo)

((Sneha.SK@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10